Author + information
- Dong–Ho Shin,
- Jung–Sun Kim,
- Byeong–Keuk Kim,
- Young–Guk Ko,
- Bum–Kee Hong,
- Donghoon Choi,
- Myeong–Ki Hong,
- Hyuck Moon Kwon and
- Yangsoo Jang
Drug–eluting stents (DES) improved prognosis after percutaneous coronary intervention. This study sought to compare long–term clinical outcomes of 1st generation DES, Sirolimus–Eluting Stent (SES) versus Paclitaxel–Eluting Stent (PES) during 7 years.
Between Nov. 1998 and Feb 2012, total 3292 patients received intracoronary SES (2282) and PES (1010). Primary endpoint was the composite of cardiovascular deaths, myocardial infarction (MI), stent thrombosis (ST), and target lesion revascularization (TLR) during 7 years.
During the observation of 13,029.3 person–years (median 4.1 years), there were 65 deaths (2.8%), 38 MI (1.7%), 22 ST (0.9%), and 247 TLR (12.2%). Although patients with SES developed fewer clinical events than those with PES during the first 3 years (HR 0.57, 95% CI 0.44~0.75, p<0.001), cumulative incidences became similar at 7 years between the groups (SES 15.0% vs. PES 14.5%, p=0.07) because of the higher event rate in patients with SES after 3 years (HR 1.92, 95% CI 1.18~3.12, p=0.009). (Figure 1~2). This ‘late catch–up phenomenon’ was mainly driven by TLR, while incidences of cardiovascular deaths, MI and ST were similar throughout 7 years. (Figure 3)
Comparing clinical events of SES and PES during 7 years, the ‘late catch–up phenomenon’ was observed because of fewer TLR in patients with SES until 3 years and more TLR after that.
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.–10:45 a.m.
Session Title: Coronary Stents
Abstract Category: 47. TCT@ACC–i2: Coronary Intervention, Devices
Presentation Number: 2101–219
- 2013 American College of Cardiology Foundation